Integrative therapies for managing symptoms in multiple myeloma
Official title: Effectiveness and Safety of Integrative Therapies in Multiple Myeloma
Run by Bnai Zion Medical Center · NCT06515249 · Data updated 2026-11-12
This study is testing if combining different treatments can help people with multiple myeloma feel better and improve their quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Bnai Zion Medical Center Government |
| Locations | 1 site (Haifa) |
| Status | Recruiting |
| Started | July 15, 2024 |
| Main results expected | July 2028 |
| Study ends | July 2028 |
| Registry record updated | September 30, 2026 |
| Trial ID | NCT06515249 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who have been diagnosed with multiple myeloma and can communicate in Hebrew, Arabic, or Russian.
✕Probably not a fit
Patients under 18 years old, those with severe platelet deficiencies, or individuals with psychiatric disorders that impair their ability to participate may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on the use of integrative medicine to address the various symptoms experienced by patients with multiple myeloma, a chronic hematologic malignancy. It aims to improve quality of life by employing both pharmacological and non-pharmacological treatments tailored to the individual needs of patients. Participants will be required to complete monthly questionnaires to assess their symptoms and overall well-being. The study emphasizes the importance of quality-of-life outcomes in the management of this disease.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life for patients suffering from multiple myeloma by effectively managing their symptoms.
How similar studies have gone: While integrative approaches in managing chronic conditions have shown promise, this specific study's methodology is relatively novel in the context of multiple myeloma.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 18 * Diagnosis of multiple myeloma * Possibility to answer questionnaires once a month in Hebrew, Arabic or Russian * Signing an informed consent form Exclusion Criteria: * Age under 18 years * In patients who will receive acupuncture: platelet level below 20x10\^9/L * In patients who will receive reflexology: deep vein thrombosis in the leg * Hemodynamic instability * Psychiatric disorder impairing competence
Where it's running
-
Bnai Zion Medical Center
Haifa, Israel Recruiting
Study contacts
- Principal investigator: Ilana Levy Yurkovski, MD — Bnai Zion Medical Center, Haifa, Israel
- Study coordinator: Ilana Levy Yurkovski, MD
- Email: ilana.levy@b-zion.org.il
- Phone: +972525086128
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma
This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
-
Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma
This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.